Abstract
Mammalian thioredoxin reductase (TrxR) is a selenoprotein with three existing isoenzymes (TrxR1, TrxR2, and TrxR3), which is found primarily intracellularly but also in extracellular fluids. The main substrate thioredoxin (Trx) is similarly found (as Trx1 and Trx2) in various intracellular compartments, in blood plasma, and is the cell’s major disulfide reductase. Thioredoxin reductase is necessary as a NADPH-dependent reducing agent in biochemical reactions involving Trx. Genetic and environmental factors like selenium status influence the activity of TrxR. Research shows that the Trx/TrxR system plays a significant role in the physiology of the adipose tissue, in carbohydrate metabolism, insulin production and sensitivity, blood pressure regulation, inflammation, chemotactic activity of macrophages, and atherogenesis. Based on recent research, it has been reported that the modulation of the Trx/TrxR system may be considered as a new target in the management of the metabolic syndrome, insulin resistance, and type 2 diabetes, as well as in the treatment of hypertension and atherosclerosis. In this review evidence about a possible role of this system as a marker of the metabolic syndrome is reported.
Similar content being viewed by others
Abbreviations
- HIV:
-
Human immunodeficiency virus
- NADPH:
-
Nicotinamide adenine dinucleotide phosphate
- PPAR-γ:
-
Peroxisome-proliferator-activated receptor-gamma
- Se:
-
Selenium
- Trx:
-
Thioredoxin
- TrxR:
-
Thioredoxin reductase
- TXNRD:
-
Thioredoxin reductase
References
Zhang J, Svehlíková V, Bao Y, Howie AF, Beckett GJ, Williamson G (2003) Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation. Carcinogenesis 24:497–503
Campbell L, Howie F, Arthur JR, Nicol F, Beckett G (2007) Selenium and sulforaphane modify the expression of selenoenzymes in the human endothelial cell line EAhy926 and protect cells from oxidative damage. Nutrition 23:138–144 (Erratum in: Nutrition; 23:378)
Wataha JC, Lewis JB, McCloud VV, Shaw M, Omata Y, Lockwood PE, Messer RL, Hansen JM (2008) Effect of mercury(II) on Nrf2, thioredoxin reductase-1 and thioredoxin-1 in human monocytes. Dent Mater 24:765–772
Crane MS, Howie AF, Arthur JR, Nicol F, Crosley LK, Beckett GJ (2009) Modulation of thioredoxin reductase-2 expression in EAhy926 cells: implications for endothelial selenoprotein hierarchy. Biochim Biophys Acta 1790:1191–1197
Erkhembayar S, Mollbrink A, Eriksson M, Larsen EH, Eriksson LC (2011) Selenium homeostasis and induction of thioredoxin reductase during long term selenite supplementation in the rat. J Trace Elem Med Biol 25:254–259
Barrera LN, Cassidy A, Wang W, Wei T, Belshaw NJ, Johnson IT, Brigelius-Flohé R, Bao Y (2012) TrxR1 and GPx2 are potently induced by isothiocyanates and selenium, and mutually cooperate to protect Caco-2 cells against free radical-mediated cell death. Biochim Biophys Acta 1823:1914–1924
Yan J, Zheng Y, Min Z, Ning Q, Lu S (2013) Selenium effect on selenoprotein transcriptome in chondrocytes. Biometals 26:285–296
Liu H, Xu H, Huang K (2017) Selenium in the prevention of atherosclerosis and its underlying mechanisms. Metallomics 9(1):21–37
Nagarajan N, Oka S, Sadoshima J (2016) Modulation of signaling mechanisms in the heart by thioredoxin 1. Free Radic Biol Med. https://doi.org/10.1016/j.freeradbiomed.2016.12.020
Lu J, Holmgren A (2014) The thioredoxin antioxidant system. Free Radic Biol Med 66:75–87
D’Annunzio V, Perez V, Boveris A, Gelpi RJ, Poderoso JJ (2016) Role of thioredoxin-1 in ischemic preconditioning, postconditioning and aged ischemic hearts. Pharmacol Res 109:24–31
Du C, Wu M, Liu H, Ren Y, Du Y, Wu H, Wei J, Liu C, Yao F, Wang H, Zhu Y, Duan H, Shi Y (2016) Thioredoxin-interacting protein regulates lipid metabolism via Akt/mTOR pathway in diabetic kidney disease. Int J Biochem Cell Biol 79:1–13
Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273:20096–20101
Powers HJ, Hill MH, Mushtaq S, Dainty JR, Majsak-Newman G, Williams EA (2011) Correcting a marginal riboflavin deficiency improves hematologic status in young women in the United Kingdom (RIBOFEM). Am J Clin Nutr 93:1274–1284
Naghashpour M, Amani R, Nutr R, Nematpour S, Haghighizadeh MH (2011) Riboflavin status and its association with serum hs-CRP levels among clinical nurses with depression. J Am Coll Nutr 30:340–347
Yang J, Hamid S, Liu Q, Cai J, Xu S, Zhang Z (2017) Gene expression of selenoproteins can be regulated by thioredoxin(Txn) silence in chicken cardiomyocytes. J Inorg Biochem 177:118–126
Sunde RA, Raines AM, Barnes KM, Evenson JK (2009) Selenium status highly regulates selenoprotein mRNA levels for only a subset of the selenoproteins in the selenoproteome. Biosci Rep 29:329–338
Rundlöf AK, Arnér ES (2004) Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6:41–52
Steinbrenner H, Speckmann B, Klotz LO (2016) Selenoproteins: antioxidant selenoenzymes and beyond. Arch Biochem Biophys 595:113–119
Zhang X, Zhang L, Zhu JH, Cheng WH (2016) Nuclear selenoproteins and genome maintenance. IUBMB Life 68:5–12
Eklund H, Gleason FK, Holmgren A (1991) Structural and functional relations among thioredoxins of different species. Proteins 11:13–28
Holmgren A (1995) Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3(3):239–243
Montano SJ, Lu J, Gustafsson TN, Holmgren A (2014) Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples. Anal Biochem 449:139–146
Laurent TC, Moore EC, Reichard P (1964) Enzymatic synthesis of deoxyribonucletides IV Isolation and characterization of thioredoxn, the hydrogen donor from Escherichia coli B. J Biol Chem 239:3436–3444
Holmgren A (1985) Thioredoxin. Annu Rev Biochem 54:237–271
Martin JL (1995) Thioredoxin–a fold for all reasons. Structure 3(3):245–250
Lillig CH, Holmgren A (2007) Thioredoxin and related molecules-from biology to health and disease. Antioxid Redox Signal 9:25–47
Arnér ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267(20):6102–6109
Rhee SG, Kil IS (2017) Multiple functions and regulation of mammalian peroxiredoxins. Annu Rev Biochem 86:749–775
Kallis GB, Holmgren A (1980) Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from Escherichia coli. J Biol Chem 255(21):10261–10265
Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Herzenberg LA, Ghezzi P (1999) Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189(11):1783–1789
Pekkari K, Gurunath R, Arner ES, Holmgren A (2000) Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275(48):37474–37480
Gil-Bea F, Akterin S, Persson T, Mateos L, Sandebring A, Avila-Cariño J, Gutierrez-Rodriguez A, Sundström E, Holmgren A, Winblad B, Cedazo-Minguez A (2012) Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer’s disease brain. EMBO Mol Med 4(10):1097–1111
Couchie D, Vaisman B, Abderrazak A, Mahmood DFD, Hamza MM, Canesi F, Diderot V, El Hadri K, Nègre-Salvayre A, Le Page A, Fulop T, Remaley AT, Rouis M (2017) Human plasma thioredoxin-80 increases with age and in ApoE(−/−) mice induces inflammation, angiogenesis, and atherosclerosis. Circulation 136(5):464–475
Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, Becker K (2011) Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat Commun 2:383
Park BJ, Cha MK, Kim IH (2014) Thioredoxin 1 as a serum marker for ovarian cancer and its use in combination with CA125 for improving the sensitivity of ovarian cancer diagnoses. Biomarkers 19(7):604–610
Chong CR, Chan WPA, Nguyen TH, Liu S, Procter NE, Ngo DT et al (2014) Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther 28(4):347–360
Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA (2001) Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98:2688–2693
Hofer S, Rosenhagen C, Nakamura H, Yodoi J, Bopp C, Zimmermann JB, Goebel M, Schemmer P, Hoffmann K, Schulze-Osthoff K, Breitkreutz R, Weigand MA (2009) Thioredoxin in human and experimental sepsis. Crit Care Med 37:2155–2159
Nakamura H, Hoshino Y, Okuyama H, Matsuo Y, Yodoi J (2009) Thioredoxin 1 delivery as new therapeutics. Adv Drug Deliv Rev 61:303–309
Matsuo Y, Yodoi J (2013) Extracellular thioredoxin: a therapeutic tool to combat inflammation. Cytokine Growth Factor Rev 24:345–353
Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23(3B):2425–2433
Powis G, Mustacich D, Coon A (2000) The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29(3–4):312–322
Arnér ES, Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16(6):419
Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK (2015) Thioredoxin 1 in prostate tissue is associated with gleason score, erythrocyte antioxidant enzyme activity, and dietary antioxidants. Prostate Cancer 2015(2015):728046
O’Connell K, Ohlendieck K (2009) Proteomic DIGE analysis of the mitochondria-enriched fraction from aged rat skeletal muscle. Proteomics 9:5509–5524
Catani MV, Savini I, Duranti G, Caporossi D, Ceci R, Sabatini S, Avigliano L (2004) Nuclear factor kappaB and activating protein 1 are involved in differentiation-related resistance to oxidative stress in skeletal muscle cells. Free Radic Biol Med 37:1024–1036
Picard M, Jung B, Liang F, Azuelos I, Hussain S, Goldberg P, Godin R, Danialou G, Chaturvedi R, Rygiel K, Matecki S, Jaber S, Des Rosiers C, Karpati G, Ferri L, Burelle Y, Turnbull DM, Taivassalo T, Petrof BJ (2012) Mitochondrial dysfunction and lipid accumulation in the human diaphragm during mechanical ventilation. Am J Respir Crit Care Med 186:1140–1149
Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M (2004) Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24:9414–9423
Matsushima S, Ide T, Yamato M, Matsusaka H, Hattori F, Ikeuchi M, Kubota T, Sunagawa K, Hasegawa Y, Kurihara T, Oikawa S, Kinugawa S, Tsutsui H (2006) Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113:1779–1786
Tsutsui H, Kinugawa S, Matsushima S (2008) Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 72(Suppl A):A31–A37
Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81:449–456
Kumar V, Kitaeff N, Hampton MB, Cannell MB, Winterbourn CC (2009) Reversible oxidation of mitochondrial peroxiredoxin 3 in mouse heart subjected to ischemia and reperfusion. FEBS Lett 583:997–1000
Lijnen PJ, Piccart Y, Coenen T, Prihadi JS (2012) Angiotensin II-induced mitochondrial reactive oxygen species and peroxiredoxin-3 expression in cardiac fibroblasts. J Hypertens 30:1986–1991
Murphy MP (2012) Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid Redox Signal 16:476–495
Mowbray AL, Kang DH, Rhee SG, Kang SW, Jo H (2008) Laminar shear stress up-regulates peroxiredoxins (PRX) in endothelial cells: PRX 1 as a mechanosensitive antioxidant. J Biol Chem 283:1622–1627
Lowes DA, Galley HF (2010) Mitochondrial protection by the thioredoxin-2 and GSH systems in an in vitro endothelial model of sepsis. Biochem J 436:123–132
Munro D, Treberg JR (2017) A radical shift in perspective: mitochondria as regulators of reactive oxygen species. J Exp Biol 220(Pt 7):1170–1180
Munro D, Banh S, Sotiri E, Tamanna N, Treberg JR (2016) The thioredoxin and glutathione-dependent H2O2 consumption pathways in muscle mitochondria: involvement in H2O2 metabolism and consequence to H2O2 efflux assays. Free Radic Biol Med 96:334–346
Lothrop AP, Snider GW, Ruggles EL, Patel AS, Lees WJ, Hondal RJ (2014) Selenium as an electron acceptor during the catalytic mechanism of thioredoxin reductase. Biochemistry 53(4):654–663
Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G (2001) Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci USA 98:9533–9538
Cheng Q, Sandalova T, Lindqvist Y, Arnér ES (2009) Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284:3998–4008
Lu J, Chew EH, Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104:12288–12293
Bragadin M, Scutari G, Folda A, Bindoli A, Rigobello MP (2004) Effect of metal complexes on thioredoxin reductase and the regulation of mitochondrial permeability conditions. Ann N Y Acad Sci 1030:348–354
El-Sharaky AS, Newairy AA, Badreldeen MM, Eweda SM, Sheweita SA (2007) Protective role of selenium against renal toxicity induced by cadmium in rats. Toxicology. 235:185–193 (Erratum in: Toxicology. 2007;242:160)
Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A (2008) Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 283:11913–11923
Branco V, Canário J, Holmgren A, Carvalho C (2011) Inhibition of the thioredoxin system in the brain and liver of zebra-seabreams exposed to waterborne methylmercury. Toxicol Appl Pharmacol 251:95–103. https://doi.org/10.1016/j.taap.2010.12.005
Carvalho CM, Lu J, Zhang X, Arnér ES, Holmgren A (2011) Effects of selenite and chelating agents on mammalian thioredoxin reductase inhibited by mercury: implications for treatment of mercury poisoning. FASEB J 25:370–381. https://doi.org/10.1096/fj.10-157594
Branco V, Canário J, Lu J, Holmgren A, Carvalho C (2012) Mercury and selenium interaction in vivo: effects on thioredoxin reductase and glutathione peroxidase. Free Radic Biol Med 52:781–793
Branco V, Ramos P, Canário J, Lu J, Holmgren A, Carvalho C (2012) Biomarkers of adverse response to mercury: histopathology versus thioredoxin reductase activity. J Biomed Biotechnol 2012:359879. https://doi.org/10.1155/2012/359879
Saccoccia E, Angelucci F, Boumis G, Carotti D, Desiato G, Miele AE, Bellelli A (2014) Thioredoxin reductase and its inhibitors. Curr Protein Pept Sci 15:621–646
Venardos K, Harrison G, Headrick J, Perkins A (2004) Effects of dietary selenium on glutathione peroxidase and thioredoxin reductase activity and recovery from cardiac ischemia–reperfusion. J Trace Elem Med Biol 18(1):81–88
Mahmood DF, Abderrazak A, El Hadri K, Simmet T, Rouis M (2013) The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal 19(11):1266–1303
World CJ, Yamawaki H, Berk BC (2006) Thioredoxin in the cardiovascular system. J Mol Med (Berl). 84(12):997–1003
Ebrahimian T, Touyz RM (2008) Thioredoxin in vascular biology: role in hypertension. Antioxid Redox Signal 10(6):1127–1136
Crunkhorn S (2017) Cardiovascular disease: thioredoxin lowers hypertension. Nat Rev Drug Discov 16(4):240
Eren E, Aykal G, Sayrac S, Erol O, Ellidag HY, Yilmaz N (2017) Relationship between thioredoxin and thioredoxin-binding protein in patients with gestational diabetes mellitus. J Matern Fetal Neonatal Med 30(2):164–168
Nakatsukasa Y, Tsukahara H, Tabuchi K, Tabuchi M, Magami T, Yamada M, Fujii Y, Yashiro M, Tsuge M, Morishima T (2013) Thioredoxin-1 and oxidative stress status in pregnant women at early third trimester of pregnancy: relation to maternal and neonatal characteristics. J Clin Biochem Nutr 52(1):27–31
Yu L, Fan C, Li Z, Zhang J, Xue X, Xu Y, Zhao G, Yang Y, Wang H (2017) Melatonin rescues cardiac thioredoxin system during ischemia–reperfusion injury in acute hyperglycemic state by restoring Notch1/Hes1/Akt signaling in a membrane receptor-dependent manner. J Pineal Res. https://doi.org/10.1111/jpi.12375
Karunasinghe N, Han DY, Zhu S, Duan H, Ko YJ, Yu JF, Triggs CM, Ferguson LR (2013) Effects of supplementation with selenium, as selenized yeast, in a healthy male population from New Zealand. Nutr Cancer 65:355–366
Grundy SM (2005) Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Atherosclerosis Thromb Vasc Physiol 25(11):2243–2244
Bricker LA, Greydanus DE (2008) The metabolic syndrome: a gathering challenge in a time of abundance. Adolesc Med State Art Rev 19(3):475–497
Dietrich P, Hellerbrand C (2014) Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 28(4):637–653
Kaimul AM, Nakamura H, Masutani H, Yodoi J (2007) Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 43(6):861–868
Peña-Orihuela P, Camargo A, Rangel-Zuñiga OA, Perez-Martinez P, Cruz-Teno C, Delgado-Lista J, Roche HM (2013) Antioxidant system response is modified by dietary fat in adipose tissue of metabolic syndrome patients. J Nutr Biochem 24(10):1717–1723
Palmieri VO, Coppola B, Grattagliano I, Casieri V, Cardinale G, Portincasa P et al (2013) Oxidized LDL receptor 1 gene polymorphism in patients with metabolic syndrome. Eur J Clin Investig 43(1):41–48
Jankovic A, Korac A, Buzadzic B, Otasevic V, Stancic A, Daiber A, Korac B (2015) Redox implications in adipose tissue (dys) function—a new look at old acquaintances. Redox Biol 6:19–32
Jankovic A, Korac A, Srdic-Galic B, Buzadzic B, Otasevic V, Stancic A, Korac B (2014) Differences in the redox status of human visceral and subcutaneous adipose tissues—relationships to obesity and metabolic risk. Metabolism 63(5):661–671
Zhou C, Routh VH (2017) Thioredoxin-1 overexpression in the ventromedial nucleus of the hypothalamus (VMH) preserves the counterregulatory response to hypoglycemia during type 1 diabetes mellitus in male rats. Diabetes. https://doi.org/10.2337/db17-0930
Yang J, Hamid S, Cai J, Liu Q, Xu S, Zhang Z (2017) Selenium deficiency-induced thioredoxin suppression and thioredoxin knock down disbalanced insulin responsiveness in chicken cardiomyocytes through PI3K/Akt pathway inhibition. Cell Signal 38:192–200
Steinbrenner H (2013) Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. Free Radic Biol Med 65:1538–1547
Peng X, Giménez-Cassina A, Petrus P, Conrad M, Rydén M, Arnér ES (2016) Thioredoxin reductase 1 suppresses adipocyte differentiation and insulin responsiveness. Sci Rep 6:28080. https://doi.org/10.1038/srep28080
Claessens M, Saris WH, Bouwman FG, Evelo CT, Hul GB, Blaak EE, Mariman EC (2007) Differential valine metabolism in adipose tissue of low and high fat-oxidizing obese subjects. Proteom Clin Appl 1(10):1306–1315
Heinonen S, Buzkova J, Muniandy M, Kaksonen R, Ollikainen M, Ismail K, Hakkarainen A, Lundbom J, Lundbom N, Vuolteenaho K, Moilanen E, Kaprio J, Rissanen A, Suomalainen A, Pietiläinen KH (2015) Impaired mitochondrial biogenesis in adipose tissue in acquired obesity. Diabetes 64(9):3135–3145
Yin X, Sun C, Cui Y (2006) Study of different expressed proteins between white adipose tissue of patients with type 2 diabetes mellitus and controls [J]. Shandong Med J 7:002
Lejnev K, Khomsky L, Bokvist K, Mistriel-Zerbib S, Naveh T, Farb TB, Alsina-Fernandez J, Atlas D (2016) Thioredoxin-mimetic peptides (TXM) inhibit inflammatory pathways associated with high-glucose and oxidative stress. Free Radic Biol Med 99:557–571
Anca PL, Bogdana V, Olivia T, Horia V, Dumitru O, Leon Z (2014) P70—the relations between immunity, oxidative stress and inflammation markers, in childhood obesity. Free Radic Biol Med 75:S44–S45
Kursawe R, Caprio S, Giannini C, Narayan D, Lin A, D’Adamo E, Shulman GI (2013) Decreased transcription of ChREBP-α/β isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes associations with insulin resistance and hyperglycemia. Diabetes 62(3):837–844
Jiménez-Osorio AS, González-Reyes S, García-Niño WR, Moreno-Macías H, Rodríguez-Arellano ME, Vargas-Alarcón G, Zúñiga J, Barquera R, Pedraza-Chaverri J (2016) Association of nuclear factor-erythroid 2-related factor 2, thioredoxin interacting protein, and heme oxygenase-1 gene polymorphisms with diabetes and obesity in mexican patients. Oxid Med Cell Longev 2016:7367641
Bouwman FG, Claessens M, van Baak MA, Noben JP, Wang P, Saris WH, Mariman EC (2009) The physiologic effects of caloric restriction are reflected in the in vivo adipocyte-enriched proteome of overweight/obese subjects. J Proteome Res 8(12):5532–5540
Huh JY, Kim Y, Jeong J, Park J, Kim I, Huh KH, Kim YS, Woo HA, Rhee SG, Lee KJ, Ha H (2012) Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal 16:229–243
Roca-Rivada A, Alonso J, Al-Massadi O, Castelao C, Peinado JR, Seoane LM et al (2011) Secretome analysis of rat adipose tissues shows location-specific roles for each depot type. J Proteom 74(7):1068–1079
Chiellini C, Cochet O, Negroni L, Samson M, Poggi M, Ailhaud G et al (2008) Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol 9(1):1
Adachi J, Kumar C, Zhang Y, Mann M (2007) In-depth analysis of the adipocyte proteome by mass spectrometry and bioinformatics. Mol Cell Proteom 6(7):1257–1273
Vanella L, Li M, Rezzani R, Rodella L, Martasek P, Peterson SJ, Abraham NG (2010) Perturbations in redox homeostasis in visceral fat due to decreases in HO-1, adiponectin and pAMPK adversely effects vascular function in obese mice. Circulation 122(Suppl 21):A19686
Rojanathammanee L, Rakoczy S, Kopchick J, Brown-Borg HM (2014) Effects of insulin-like growth factor 1 on glutathione S-transferases and thioredoxin in growth hormone receptor knockout mice. Age (Dordrecht) 36(4):9687
Xing SQ, Zhang CG, Yuan JF, Yang HM, Zhao SD, Zhang H (2015) Adiponectin induces apoptosis in hepatocellular carcinoma through differential modulation of thioredoxin proteins. Biochem Pharmacol 93(2):221–231
Liu JS, Xu JY, Huang J, Zhao Y, Ye F, Zhong LW (2016) A reciprocal inhibitory relationship between adiponectin and mammalian cytosolic thioredoxin. Sci Bull 61(19):1513–1521
Rindler PM, Plafker SM, Szweda LI, Kinter M (2013) High dietary fat selectively increases catalase expression within cardiac mitochondria. J Biol Chem 288(3):1979–1990
Zagrodzki PAWEŁ, Joniec A, Gawlik MAŁGORZATA, Gawlik M, Krosniak M, Folta M, Zachwieja ZOFIA (2007) High fructose model of oxidative stress and metabolic disturbances in rats. Part I. Antioxidant status of rats’ tissues. Bull Vet Inst Pulawy 51(3):407
Fisher-Wellman KH, Mattox TA, Thayne K, Katunga LA, La Favor JD, Neufer PD, Hickner RC, Wingard CJ, Anderson EJ (2013) Novel role for thioredoxin reductase-2 in mitochondrial redox adaptations to obesogenic diet and exercise in heart and skeletal muscle. J Physiol 591(14):3471–3486
Qin H, Zhang X, Ye F, Zhong L (2014) High-fat diet-induced changes in liver thioredoxin and thioredoxin reductase as a novel feature of insulin resistance. FEBS Open Bio 31(4):928–935
Salmon A, Flores LC, Li Y, Van Remmen H, Richardson A, Ikeno Y (2012) Reduction of glucose intolerance with high fat feeding is associated with anti-inflammatory effects of thioredoxin 1 overexpression in mice. Pathobiol Aging Age Relat Dis 2:17101
Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT (2006) The interaction of thioredoxin with Txnip evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281(31):21884–21891
Chutkow WA, Lee RT (2011) Thioredoxin regulates adipogenesis through thioredoxin-interacting protein (Txnip) protein stability. J Biol Chem 286(33):29139–29145
Chutkow WA, Birkenfeld AL, Brown JD, Lee HY, Frederick DW, Yoshioka J, Shulman GI (2010) Deletion of the α-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 59(6):1424–1434
Koenen TB, Stienstra R, Van Tits LJ, De Graaf J, Stalenhoef AF, Joosten LA, Netea MG (2011) Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1β transcription in human adipose tissue. Diabetes 60(2):517–524
Giordano A, Murano I, Mondini E, Perugini J, Smorlesi A, Severi I et al (2013) Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res 54(9):2423–2436
Rajalin AM, Micoogullari M, Sies H, Steinbrenner H (2014) Upregulation of the thioredoxin-dependent redox system during differentiation of 3T3-L1 cells to adipocytes. Biol Chem 395(6):667–677
Song JS, Cho HH, Lee BJ, Bae YC, Jung JS (2010) Role of thioredoxin 1 and thioredoxin 2 on proliferation of human adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 20(9):1529–1537
Karasawa H, Takaishi K, Kumagae Y (2011) Obesity-induced diabetes in mouse strains treated with gold thioglucose: a novel animal model for studying β-cell dysfunction. Obesity (Silver Spring) 19(3):514–521
Zhao Y, Li X, Tang S (2015) Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early type 2 diabetes mellitus. Diabetes Res Clin Pract 109(2):372–377
Blouet C, Liu SM, Jo YH, Chua S, Schwartz GJ (2012) TXNIP in Agrp neurons regulates adiposity, energy expenditure, and central leptin sensitivity. J Neurosci 32(29):9870–9877
Pitts MW, Reeves MA, Hashimoto AC, Ogawa A, Kremer P, Seale LA, Berry MJ (2013) Deletion of selenoprotein M leads to obesity without cognitive deficits. J Biol Chem 288(36):26121–26134
Liang Y, Lin SL, Wang CW, Yao HD, Zhang ZW, Xu SW (2014) Effect of selenium on selenoprotein expression in the adipose tissue of chickens. Biol Trace Elem Res 160(1):41–48
Pinto A, Juniper DT, Sanil M, Morgan L, Clark L, Sies H et al (2012) Supranutritional selenium induces alterations in molecular targets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs. J Inorg Biochem 114:47–54
Kim CH, Younossi ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Clevel Clin J Med 75(10):721–728
Okuyama H, Son A, Ahsan M, Masutani H, Nakamura H, Yodoi J (2008) Thioredoxin and thioredoxin binding protein 2 in the liver. IUBMB Life 60(10):656–660
Okanoue T, Yamauchi N, Furutani M, Hirohama A, Sumida Y, Nakashima T (2005) Predictors of nonalcoholic steatohepatitis in Japanese patients: thioredoxin and NASH. In: Okita K (ed) NASH and nutritional therapy. Springer, Tokyo, pp 64–72
Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, Kashima K (2003) Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 38(1):32–38
Nakashima T, Sumida Y, Furutani M, Hirohama A, Okita M, Mitsuyoshi H, Okanoue T (2005) Elevation of serum thioredoxin levels in patients with nonalcoholic steatohepatitis. Hepatol Res 33(2):135–137
Mitsuyoshi H, Itoh Y, Okanoue T (2006) Role of oxidative stress in non-alcoholic steatohepatitis. Nihon rinsho Jpn J Clin Med 64(6):1077–1082
Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T (2008) Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 42(4):413–418
Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, Feldstein AE (2011) Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal 15(2):437–445
Grattagliano I, Caraceni P, Calamita G, Ferri D, Gargano I, Palasciano G, Portincasa P (2008) Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Investig 38(7):523–530
Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W et al (2012) Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One 7(1):e28784
Xiao J, Liu Y, Xing F, Leung TM, Liong EC, Tipoe GL (2016) Bee’s honey attenuates non-alcoholic steatohepatitis-induced hepatic injury through the regulation of thioredoxin-interacting protein—NLRP3 inflammasome pathway. Eur J Nutr 55:1–13
Donnelly KL, Margosian MR, Sheth SS, Lusis AJ, Parks EJ (2004) Increased lipogenesis and fatty acid reesterification contribute to hepatic triacylglycerol stores in hyperlipidemic Txnip−/− mice. J Nutri 134(6):1475–1480
Haque JA, McMahan RS, Campbell JS, Shimizu-Albergine M, Wilson AM, Botta D et al (2010) Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab Investig 90(12):1704–1717
Shearn CT, Mercer KE, Orlicky DJ, Hennings L, Smathers-McCullough RL, Stiles BL et al (2014) Short term feeding of a high fat diet exerts an additive effect on hepatocellular damage and steatosis in liver-specific PTEN knockout mice. PLoS One 9(5):e96553
Duan XY, Zhao HP, Fan JG (2010) Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease. J Dig Dis 11(2):94–100
Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Ashford ML (2014) Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol 34(17):3305–3320
Lu H, Cui W, Klaassen CD (2011) Nrf2 protects against 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. Toxicol Appl Pharmacol 256(2):122–135
Kakisaka Y, Nakashima T, Sumida Y, Yoh T, Nakamura H, Yodoi J, Senmaru H (2002) Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm Metab Res 34:160–164
Miyamoto S, Kawano H, Hokamaki J, Soejima H, Kojima S, Kudoh T, Nakamura H (2005) Increased plasma levels of thioredoxin in patients with glucose intolerance. Intern Med 44(11):1127–1132
Ikegami H, Ono M, Fujisawa T, Hiromine Y, Kawabata Y, Yamato E (2008) Molecular scanning of the gene for thioredoxin, an antioxidative and antiapoptotic protein, and genetic susceptibility to type 1 diabetes. Ann N Y Acad Sci 1150(1):103–105
Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C, Castellino P (2007) Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 12(4):299–306
Calabrese V, Cornelius C, Leso V, Trovato-Salinaro A, Ventimiglia B, Cavallaro M, Castellino P (2012) Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim Biophys Acta (BBA) Mol Basis Dis 1822(5):729–736
Aaseth J, Stoa-Birketvedt G (2000) Glutathione in overweight patients with poorly controlled type 2 diabetes. J Trace Elem Exp Med 13(1):105–111
Hamada Y, Fujii H, Kitazawa R, Yodoi J, Kitazawa S, Fukagawa M (2009) Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone 44(5):936–941
Hotta M, Tashiro F, Ikegami H, Niwa H, Ogihara T, Yodoi J, Miyazaki JI (1998) Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 188(8):1445–1451
Yamamoto M, Yamato E, Shu-Ichi T, Tashiro F, Ikegami H, Yodoi J, Miyazaki JI (2007) Transgenic expression of antioxidant protein thioredoxin in pancreatic β cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal 10(1):43–50
Chernatynskaya AV, Looney B, Hu H, Zhu X, Xia CQ (2011) Administration of recombinant human thioredoxin-1 significantly delays and prevents autoimmune diabetes in nonobese diabetic mice through modulation of autoimmunity. Diabetes Metab Res Rev 27(8):809–812
Muoio DM (2007) TXNIP links redox circuitry to glucose control. Cell Metab 5(6):412–414
Li X, Rong Y, Zhang M, Wang XL, LeMaire SA, Coselli JS, Shen YH (2009) Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 381(4):660–665
Lappalainen Z, Lappalainen J, Oksala NK, Laaksonen DE, Khanna S, Sen CK, Atalay M (2009) Diabetes impairs exercise training-associated thioredoxin response and glutathione status in rat brain. J Appl Physiol 106(2):461–467
Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G (2009) Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 52(4):636–644
Robinson KA, Brock JW, Buse MG (2013) Posttranslational regulation of thioredoxin-interacting protein. J Mol Endocrinol 50(1):59–71
Parikh H, Carlsson E, Chutkow WA, Johansson LE, Storgaard H, Poulsen P et al (2007) TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4(5):e158
Chen J, Hui ST, Couto FM, Mungrue IN, Davis DB, Attie AD, Shalev A (2008) Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 22(10):3581–3594
Masson E, Koren S, Razik F, Goldberg H, Kwan EP, Sheu L et al (2009) High β-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice. Am J Physiol Endocrinol Metab 296(6):E1251–E1261
Xu G, Chen J, Jing G, Shalev A (2013) Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med 19(9):1141–1146
Guzmán AM, Arredondo Olguín M, Olivares Gronhert M (2015) Glycemic control and oxidative stress markers and their relationship with the thioredoxin interacting protein (TXNIP) gene in type 2 diabetic patients. Nutr Hosp 31(3):1129–1133
Wei J, Shi Y, Hou Y, Ren Y, Du C, Zhang L, Duan H (2013) Knockdown of thioredoxin-interacting protein ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Cell Signal 25(12):2788–2796
Lillig CH, Holmgren A (2007) Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal 9(1):25–47
Ghezzi P (2013) Protein glutathionylation in health and disease. Biochim Biophys Acta 1830(5):3165–3172
Zhang H, Forman HJ (2012) Glutathione synthesis and its role in redox signaling. Semin Cell Dev Biol 23(7):722–728
Benhar M, Forrester MT, Stamler JS (2009) Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol 10(10):721–732
Corbett JA (2008) Thioredoxin-interacting protein is killing my β-cells! Diabetes 57(4):797–798
Tang L, Zhang Y, Jiang Y, Willard L, Ortiz E, Wark L et al (2011) Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes. Exp Biol Med 236(9):1051–1063
Shelton MD, Kern TS, Mieyal JJ (2007) Glutaredoxin regulates nuclear factor κ-B and intercellular adhesion molecule in müller cells model of diabetic retinopathy. J Biol Chem 282(17):12467–12474
Hou X, Song J, Li XN, Zhang L, Wang X, Chen L, Shen YH (2010) Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK–FOXO3 pathway. Biochem Biophys Res Commun 396(2):199–205
Liu JH, Liu DF, Wang NN, Lin HL, Mei X (2011) Possible role for the thioredoxin system in the protective effects of probucol in the pancreatic islets of diabetic rats. Clin Exp Pharmacol Physiol 38(8):528–533
Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Maulik N (2007) Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43(5):720–729
Packer L, Kraemer K, Rimbach G (2001) Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17(10):888–895
Mueller AS, Pallauf J (2006) Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. J Nutr Biochem 17(8):548–560
Atalay M, Bilginoglu A, Kokkola T, Oksala N, Turan B (2011) Treatments with sodium selenate or doxycycline offset diabetes-induced perturbations of thioredoxin-1 levels and antioxidant capacity. Mol Cell Biochem 351(1–2):125–131
Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E (2006) Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiologic evidence. Environ Health Perspect 114:641–648
Tseng CH (2004) The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 197(2):67–83
Sun HJ, Rathinasabapathi B, Wu B, Luo J, Pu LP, Ma LQ (2014) Arsenic and selenium toxicity and their interactive effects in humans. Environ Int 69:148–158
Tatsunami R, Oba T, Takahashi K, Tampo Y (2009) Methylglyoxal causes dysfunction of thioredoxin and thioredoxin reductase in endothelial cells. J Pharmacol Sci 111(4):426–432
Luan R, Liu S, Yin T, Lau WB, Wang Q, Guo W et al (2009) High glucose sensitizes adult cardiomyocytes to ischaemia/reperfusion injury through nitrative thioredoxin inactivation. Cardiovasc Res 83(2):294–302
Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT (2004) Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279(29):30369–30374
Li J, Zhu H, Shen E, Wan L, Arnold JMO, Peng T (2010) Deficiency of rac1 blocks NADPH oxidase activation, inhibits endoplasmic reticulum stress, and reduces myocardial remodeling in a mouse model of type 1 diabetes. Diabetes 59(8):2033–2042
Samuel SM, Thirunavukkarasu M, Penumathsa SV, Koneru S, Zhan L, Maulik G et al (2010) Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 121(10):1244–1255
Briones AM, Touyz RM (2010) Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12(2):135–142
Maulik N, Das DK (2008) Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta (BBA) Gen Subj 1780(11):1368–1382
Anema SM, Walker SW, Howie AF, Arthur JR, Nicol F, Beckett GJ (1999) Thioredoxin reductase is the major selenoprotein expressed in human umbilical-vein endothelial cells and is regulated by protein kinase C. Biochem J 342(1):111–117
Wu Q, Huang K, Xu H (2003) Effects of long-term selenium deficiency on glutathione peroxidase and thioredoxin reductase activities and expressions in rat aorta. J Inorg Biochem 94(4):301–306
Mansego ML, Blesa S, Gonzalez-Albert V, Tormos MC, Saez G, Redon J, Chaves FJ (2007) Discordant response of glutathione and thioredoxin systems in human hypertension? Antioxid Redox Signal 9(4):507–514
Mansego ML, Solar GDM, Alonso MP, Martínez F, Saez GT, Escudero JCM, Chaves FJ (2011) Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens 29(3):492–500
Ferreira NE, Omae S, Pereira A, Rodrigues MV, Miyakawa AA, Campos LC, Mill JG (2012) Thioredoxin interacting protein genetic variation is associated with diabetes and hypertension in the Brazilian general population. Atherosclerosis 221(1):131–136
Van Greevenbroek MMJ, Vermeulen VM, Feskens EJM, Evelo CT, Kruijshoop M, Hoebee B, De Bruin TWA (2007) Genetic variation in thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in diabetes mellitus. Diabet Med 24(5):498–504
Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, Yodoi J (2004) Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 6(1):89–97
Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, Bauersachs J (2009) Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of thioredoxin 2. Hypertension 54(2):338–344
Zhang H, Luo Y, Zhang W, He Y, Dai S, Zhang R et al (2007) Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol 170(3):1108–1120
Fukai T (2009) Mitochondrial thioredoxin novel regulator for NADPH oxidase and angiotensin II-induced hypertension. Hypertension 54(2):224–225
Ebrahimian T, He Y, Schiffrin EL, Touyz RM (2007) Differential regulation of thioredoxin and NAD (P) H oxidase by angiotensin II in male and female mice. J Hypertens 25(6):1263–1271
Choi H, Tostes RC, Webb RC (2011) Thioredoxin reductase inhibition reduces relaxation by increasing oxidative stress and s-nitrosylation in mouse aorta. J Cardiovasc Pharmacol 58(5):522
Choi H, Allahdadi KJ, Tostes RC, Webb RC (2011) Augmented S-nitrosylation contributes to impaired relaxation in angiotensin II hypertensive mouse aorta: role of thioredoxin reductase. J Hypertens 29(12):2359
Xu S, He Y, Vokurkova M, Touyz RM (2009) Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells role of thioredoxin. Hypertension 54(2):427–433
Trigona WL, Mullarky IK, Cao Y, Sordillo LM (2006) Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Biochem J 394(1):207–216
Koneru S, Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik N (2009) Thioredoxin-1 gene delivery induces heme oxygenase-1 mediated myocardial preservation after chronic infarction in hypertensive rats. Am J Hypertens 22(2):183–190
Park YS, Fujiwara N, Koh YH, Miyamoto Y, Suzuki K, Honke K, Taniguchi N (2002) Induction of thioredoxin reductase gene expression by peroxynitrite in human umbilical vein endothelial cells. Biol Chem 383(3–4):683–691
Schulze PC, Liu H, Choe E, Yoshioka J, Shalev A, Bloch KD, Lee RT (2006) Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26(12):2666–2672
Zhang X, Zheng Y, Fried LE, Du Y, Montano SJ, Sohn A, Lu J (2011) Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radic Biol Med 50(7):811–820
Kahlos K, Zhang J, Block ER, Patel JM (2003) Thioredoxin restores nitric oxide-induced inhibition of protein kinase C activity in lung endothelial cells. Mol Cell Biochem 254(1–2):47–54
Rodrigo R, González J, Paoletto F (2011) The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 34(4):431–440
Shioji K, Nakamura H (2003) Thioredoxin and atherosclerosis. Rinsho byori Jpn J Clin Pathol 51(11):1106–1110
Alehagen U, Aaseth J (2015) Selenium and coenzyme Q10 interrelationship in cardiovascular diseases—a clinician’s point of view. J Trace Elem Med Biol 31:157–162
Alehagen U, Aaseth J, Johansson P (2015) Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Biofactors 41(6):443–452
Alehagen U, Lindahl TL, Aaseth J, Svensson E, Johansson P (2015) Levels of sP-selectin and hs-CRP decrease with dietary intervention with selenium and coenzyme Q10 combined: a secondary analysis of a randomized clinical trial. PLoS One 10(9):e0137680. https://doi.org/10.1371/journal.pone.0137680
Wu Y, Yang L, Zhong L (2010) Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity. Atherosclerosis 212(1):351–355
Miwa K, Kishimoto C, Nakamura H, Makita T, Ishii K, Okuda N, Sasayama S (2003) Increased oxidative stress with elevated serum thioredoxin level in patients with coronary spastic angina. Clin Cardiol 26(4):177–181
Madrigal-Matute J, Fernandez-Garcia CE, Blanco-Colio LM, Burillo E, Fortuño A, Martinez-Pinna R, Martin-Ventura JL (2015) Thioredoxin-1/peroxiredoxin-1 as sensors of oxidative stress mediated by NADPH oxidase activity in atherosclerosis. Free Radic Biol Med 86:352–361
Yunfei W, Yang L, Liangwei Z (2011) 535 serum thioredoxin activity is negatively associated with total homocysteine levels in patients with coronary artery disease. Atheroscler Suppl 12(1):113–114
Miwa K, Kishimoto C, Nakamura H, Makita T, Ishii K, Okuda N, Sasayama S (2005) Serum thioredoxin and. α-tocopherol concentrations in patients with major risk factors. Circ J 69(3):291–294
Augusti PR, Ruviaro AR, Quatrin A, Somacal S, Conterato GMM, Vicentini JT et al (2012) Imbalance in superoxide dismutase/thioredoxin reductase activities in hypercholesterolemic subjects: relationship with low density lipoprotein oxidation. Lipids Health Dis 11(1):1
Cortes R, Martinez-Hervas S, Ivorra C, De Marco G, Gonzalez-Albert V, Rojo-Martínez G, Chaves FJ (2014) Enhanced reduction in oxidative stress and altered glutathione and thioredoxin system response to unsaturated fatty acid load in familial hypercholesterolemia. Clin Biochem 47(18):291–297
Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, Hirata KI et al (2001) Expression of glutaredoxin in human coronary arteries its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21(9):1483–1487
Takagi Y, Gon Y, Todaka T, Nozaki K, Nishiyama A, Sono H, Yodoi J (1998) Expression of thioredoxin ls enhanced in atherosclerotic plaques and during neointima. Lab Investig 78(8):957
Nishihira K, Hatakeyama K, Imamura T, Shibata Y, Itabe H, Nakamura H, Asada Y (2005) Thioredoxin and oxidized lipoprotein are increased in unstable plaque obtained by directional coronary atherectomy (angina pectoris, basic/clinical 5 (IHD), The 69th annual scientific meeting of the Japanese Circulation Society). Circ J 69:323
Nishihira K, Yamashita A, Imamura T, Hatakeyama K, Sato Y, Nakamura H, Asada Y (2008) Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage. Atherosclerosis 201(2):360–367
Hokamaki J, Kawano H, Soejima H, Miyamoto S, Kajiwara I, Kojima S, Yodoi J (2005) Plasma thioredoxin levels in patients with unstable angina. Int J Cardiol 99(2):225–231
Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Hokamaki J, Nakamura H (2004) Increased plasma levels of thioredoxin in patients with coronary spastic angina. Antioxid Redox Signal 6(1):75–80
Miyamoto S, Sakamoto T, Soejima H, Shimomura H, Kajiwara I, Kojima S, Nakamura H (2003) Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. Am Heart J 146(3):465–471
Okami N, Kawamata T, Yamamoto G, Okada Y, Hori T, Tachikawa T (2009) Laser microdissection-based analysis of hypoxia- and thioredoxin-related genes in human stable carotid plaques. Cardiovasc Pathol 18(5):294–300
Kim KS, Park NK, Kim SY, Kim DW, Joo SJ, Cho MC (2011) Expression of lectin like oxidized low density lipoprotein receptor-1 in the spontaneous hypertensive rat with high cholesterol diet. J Korean Soc Hypertens 17(2):57–64
Go YM, Son DJ, Park H, Orr M, Hao L, Takabe W, Jones DP (2014) Disturbed flow enhances inflammatory signaling and atherogenesis by increasing thioredoxin-1 level in endothelial cell nuclei. PLoS One 9(9):e108346
Dai G, Vaughn S, Zhang Y, Wang ET, Garcia-Cardena G, Gimbrone MA (2007) Biomechanical forces in atherosclerosis-resistant vascular regions regulate endothelial redox balance via phosphoinositol 3-kinase/Akt-dependent activation of Nrf2. Circ Res 101(7):723–733
Ungvari Z, Bagi Z, Feher A et al (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 299(1):H18–H24
Kaga S, Zhan L, Matsumoto M et al (2005) Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growthfactor. J Mol Cell Cardiol 39(5):813–822
Xu D, Li Y, Zhang B, Wang Y, Liu Y, Luo Y, Niu W, Dong M, Liu M, Dong H, Zhao P, Li Z (2016) Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats. Int J Med Sci 13(12):942–954
Wang XQ, Nigro P, Fujiwara K, Yan C, Berk BC (2012) Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2 novelty and significance. Circ Res 110(4):560–568
Byon CH, Han T, Wu J, Hui ST (2015) Txnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice. Atherosclerosis 241(2):313–321
Shimada K, Murayama T, Yokode M, Kita T, Fujita M, Kishimoto C (2011) Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Nutr Metab Cardiovasc Dis 21(9):672–678
Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S (2004) Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells a novel vasculoprotective function of statins. Circulation 110(7):856–861
Somacal S, Figueiredo CG, Quatrin A, Ruviaro AR, Conte L, Augusti PR, Duarte MM (2015) The antiatherogenic effect of bixin in hypercholesterolemic rabbits is associated to the improvement of lipid profile and to its antioxidant and anti-inflammatory effects. Mol Cell Biochem 403(1–2):243–253
Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145(3):341–355
El Hadri K, Mahmood DFD, Couchie D, Jguirim-Souissi I, Genze F, Diderot V, Rouis M (2012) Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol 32(6):1445–1452
Isakov E, Weisman-Shomer P, Benhar M (2014) Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin. Biochim Biophys Acta (BBA) Gen Subj 1840(10):3153–3161
Billiet L, Furman C, Larigauderie G, Copin C, Brand K, Fruchart JC, Rouis M (2005) Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1β expression in human monocyte-derived macrophages. J Biol Chem 280(48):40310–40318
Go YM, Halvey PJ, Hansen JM, Reed M, Pohl J, Jones DP (2007) Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion. Am J Pathol 171(5):1670–1681
Szuchman-Sapir A, Etzman M, Tamir S (2012) Human atherosclerotic plaque lipid extract impairs the antioxidant defense capacity of monocytes. Biochem Biophys Res Commun 423(4):884–888
Liu ZB, Shen X (2009) Thioredoxin reductase 1 upregulates MCP-1 release in human endothelial cells. Biochem Biophys Res Commun 386(4):703–708
Hägg D, Englund MC, Jernås M, Schmidt C, Wiklund O, Hultén LM, Svensson PA (2006) Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis 185(2):282–289
Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Kensler T (2010) Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 107(6):737–746
Acknowledgements
This paper was financially supported by the Ministry of Education and Science of the Russian Federation on the program to improve the competitiveness of Peoples’ Friendship University of Russia (RUDN University) among the world’s leading research and education centers in 2016–2020.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tinkov, A.A., Bjørklund, G., Skalny, A.V. et al. The role of the thioredoxin/thioredoxin reductase system in the metabolic syndrome: towards a possible prognostic marker?. Cell. Mol. Life Sci. 75, 1567–1586 (2018). https://doi.org/10.1007/s00018-018-2745-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-018-2745-8